

BVGH Partnership Hub Snapshot



November 2018

Dear WIPO Re:Search Members and Friends,

As the holiday season quickly approaches, we are pleased to celebrate with you the milestones we have made this year in our fight against neglected tropical diseases (NTDs), malaria, and tuberculosis. The BVGH team has established 18 new agreements and recruited seven new Members. More importantly, several WIPO Re:Search collaborations have advanced to the next stage of product development. Please check out our [WIPO Re:Search partnership pipeline](#) to see how these collaborations are moving forward.

BVGH and WIPO were in Tokyo last month to present WIPO Re:Search to members of the Japan Pharmaceutical Manufacturers Association (JPMA) and encourage Japanese companies to join the Consortium. **Eisai** and **Takeda** also described their experience participating in WIPO Re:Search and the benefits of membership for pharmaceutical companies. We thank the WIPO Japan Office for coordinating the visit and JPMA for organizing and hosting the event.

As always, please forward this Snapshot to your colleagues and reach out to us with any partnering requests or ideas.

Sincerely,
Jennifer Dent
President, BVGH



Special Announcement

[Eisai Launches Updated Website Highlighting Neglected Disease R&D Partnerships](#)



Eisai's research and development (R&D) activities are driven by the company's commitment to developing and delivering innovative medicines that address the healthcare needs of patients worldwide. Eisai participates in multiple product development partnerships with global non-profit organizations to advance R&D for NTDs, malaria, and tuberculosis. In addition to its WIPO Re:Search collaborations, Eisai's updated [website](#) showcases its partnerships with **Drugs for Neglected Diseases initiative** (DNDi), **Medicines for Malaria Venture** (MMV), and other institutions.

WIPO Re:Search Statistics



Click [here](#) for a list of WIPO Re:Search Members.
Click [here](#) for a list of WIPO Re:Search collaborations.

Cornerstones of Collaboration

GSK Provides Compounds to Aid in Antimalarial Drug Discovery



New malaria drugs with novel mechanisms of action are needed to address the growing problem of resistance to current medications. Dr. Adam Renslo, a Professor in the Department of Pharmaceutical Chemistry at the **University of California, San Francisco (UCSF)**, is exploring an innovative approach to antimalarial therapy involving inhibition of a critical *Plasmodium falciparum* signaling pathway. **GlaxoSmithKline (GSK)** will provide compounds targeting the pathway, and Dr. Renslo and collaborators will screen the compounds for biochemical activity, validate hits against whole *P. falciparum* parasites, and prioritize the confirmed hits for medicinal chemistry optimization.

BVGH FundFinder Featured Award

[Wellcome Data Re-Use Prize: Malaria](#)

The [Malaria Atlas Project](#) (MAP) launched the Repository of Open Access Data (ROAD-MAP), which contains a wealth of data on malaria risk and intervention coverage – all of which is free to be accessed, re-analyzed, and re-used by anyone. The Wellcome Trust invites participants to pursue any research question or innovation that makes best use of the ROAD-MAP data. Submissions to the prize should generate a new insight, tool, or health application.

- **Funding Amount:** £15,000
- **Funder:** Wellcome Trust
- **Deadline:** March 2019
- **Eligibility:** Open to individuals and teams

For more information about BVGH FundFinder, please email [Cathy Manner](#).



Member Spotlight

[2018 Patents for Humanity Award Ceremony](#)

The **U.S. Patent and Trademark Office (USPTO)** is recognizing innovators who use game-changing technology to meet global humanitarian challenges on November 27. Those interested in attending can [register](#).



Highlighted Contributions

Dengue fever

One of the fastest growing infectious diseases in the world, dengue infects an estimated 390 million people annually. With almost half of the world's population at risk, it is imperative that new drugs are developed that can be made available to those who need it most. To support such drug discovery efforts, this Snapshot highlights compounds that have demonstrated repurposing potential against the dengue virus:

- [AMPK activators](#)
- [CaM \(calmodulin\) receptor antagonists](#)
- [COX-2 inhibitors](#)
- [DRD2 \(dopamine d2 receptor\) antagonists](#)
- [DRD4 \(dopamine d4 receptor\) antagonists](#)

For more information or to discuss potential collaborations involving these compounds, please contact [Cathy Manner](#).

Upcoming Global Health Events

Dates	Event Name	Location
Jan. 17-21, 2019	Keystone Symposium: Tuberculosis: Mechanisms, Pathogenesis and Treatment	Banff, Canada
April 14-17, 2019	World Vaccine Congress Washington	Washington DC, USA
May 12-15, 2019	Wellcome Centre for Anti-Infectives Research (WCAIR) Conference on Innovative Drug Discovery and Development	Dundee, UK



**



*Known as EMD in the US and Canada | **Known as Merck & Co., Inc. in the US and Canada

